Table 3 Immunocytochemistry analysis related to HPV-DNA in 110 cervical samples
Human papillomavirus | N | Ki-67+ | TOP2A+ | Ki-67+/TOP2A+ | ICC+ (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N (%) | p | OR (95 % IC) | N (%) | p | OR (95 % IC) | N (%) | p | OR (95 % IC) | N (%) | p | OR (95 % IC) | ||
HPV+ | 83 | 45 (54.2) | 0.0003 | 6.809 (2.16–21.43) | 45 (54.2) | 0.0142 | 3.383 (1.29–8.86) | 36 (43.4) | 0.0004 | 9.574 (2.12–43.11) | 54 (65.1) | 0.0065 | 3.724 (1.48–9.33) |
With cytological abnormalities | 28 | 26 (92.8) | 0.0001 | 24.63 (5.26–115.2) | 20 (71.4) | 0.0357 | 3.00 (1.12–7.96) | 19 (67.8) | 0.0021 | 4.791 (1.77–12.55) | 27 (96.4) | 0.0001 | 28.00 (3.55–220.8) |
W/o cytological abnormalities | 55 | 19 (34.4) | 25 (45.4) | 17 (30.9) | 27 (49.1) | ||||||||
HPV− | 27 | 4 (14.8) | 7 (25.9) | 2 (7.4) | 9 (33.3) | ||||||||
With cytological abnormalities | 4 | 0 (−) | 0.4286 | – | 3 (75) | 1.00 | – | 0 (−) | 1.00 | – | 3 (75) | 1.00 | – |
W/o cytological abnormalities | 23 | 2 (8.7) | 3 (13.0) | 1 (4.3) | 4 (17.4) | ||||||||